STOCK TITAN

KalVista Pharmaceuticals (KALV) Debt by Year

KALV

KalVista Pharmaceuticals, Inc. held $131.6M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period. The table below carries 12 fiscal years, from 2013 to 2025, and the quarters KalVista Pharmaceuticals, Inc. has filed alongside them.

FY2025 annual
Long-Term Debt N/A
Cash & Equivalents $131.6M
Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

KALV Debt & Cash by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KTFY2410-KTFY2310-KFY2210-KFY2110-KFY2010-QFY19FilingFY1810-KFY1710-KFY1610-QFY1410-KFY1310-K
Long-Term DebtN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$2.1MN/A
Cash & Equivalents$131.6M+314.0%$31.8M-43.5%$56.2M+83.0%$30.7M-39.3%$50.6M+220.4%$15.8M-50.7%$32.0M-37.3%$51.1M+65.0%$30.9M-36.1%$48.5M$3.9M-60.2%$9.8M

KALV Debt & Cash by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ1'2610-QQ4'2510-KTQ2'2610-QQ1'2610-QQ4'2510-KTQ3'2510-QQ2'25FilingQ1'25FilingQ4'2410-KTQ3'2410-QQ2'24FilingQ1'24Filing
Long-Term Debt$172.2M$172.2M$139.0MN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cash & Equivalents$213.8M+571.2%$229.3M+621.5%$243.5M+485.6%$124.3M+290.3%$131.6M+314.0%$182.3M+690.8%$41.6M-27.9%$31.8M-35.5%$31.8M-43.5%$23.1M-72.9%$57.7M+49.5%$49.4M+30.5%

What long-term debt means

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.

More KalVista Pharmaceuticals, Inc. financials

Frequently Asked Questions

KalVista Pharmaceuticals, Inc. held $131.6M in cash and equivalents at the end of fiscal year 2025, and no long-term debt figure is on record for that period.

KalVista Pharmaceuticals, Inc. (KALV) reported $172.2M in long-term debt in Q1 2026.

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what KalVista Pharmaceuticals, Inc. (KALV) reported on that line in every period on record.